Den europeiske union - islandsk - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamíð - flogaveiki, partial - antiepileptics, - lacosamide ucb er ætlað eitt og sér og venjulega meðferð í meðferð á hluta-upphaf flog með eða án efri almenn ákvörðun er tekin í fullorðnir, unglingum og börn, frá 4 ára aldri með flogaveiki.

Den europeiske union - islandsk - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - bóluefni - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - lacosamidum inn - filmuhúðuð tafla - 100 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - lacosamidum inn - filmuhúðuð tafla - 150 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - lacosamidum inn - filmuhúðuð tafla - 200 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - lacosamidum inn - filmuhúðuð tafla - 50 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciclosporinum inn - mjúkt hylki - 100 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciclosporinum inn - mjúkt hylki - 25 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciclosporinum inn - mjúkt hylki - 50 mg

Den europeiske union - islandsk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , þrefaldur samsetning meðferð) sem viðbót til að fæði og æfing í sjúklingar ekki nægilega stjórn á eigin hámarks þolað skammt af sjúklingar og sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.